Medicare Enrolled
Dr. Michael De Luca, MD
Cardiovascular Disease · El Paso, TX
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. De Luca from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. De Luca? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. De Luca
Dr. Michael De Luca is a cardiovascular disease in El Paso, TX, with 20 years in practice. Based on federal Medicare data, Dr. De Luca performed 7,491 Medicare services across 2,955 unique beneficiaries.
Between the years covered by Open Payments, Dr. De Luca received a total of $22,854 from 30 pharmaceutical and/or device companies across 534 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. De Luca is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 7% volume in TX$ $22,854 industry payments
Medicare Practice Summary
Medicare Utilization ↗7,491
Medicare services
Top 7% in TX for cardiovascular disease
2,955
Unique beneficiaries
$91
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~375 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Contrast dye for imaging (iodine-based) | 2,539 | $0 | $0 |
| Office visit, established patient (30-39 min) | 1,441 | $85 | $309 |
| Regadenoson injection (Lexiscan) for heart stress test | 647 | $40 | $232 |
| Electrocardiogram (EKG), 12-lead | 474 | $10 | $48 |
| Echocardiogram, transthoracic | 254 | $136 | $642 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 192 | $50 | $216 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 156 | $29 | $119 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 152 | $975 | $3,823 |
| Remote patient monitoring management, 20 min/month | 139 | $36 | $147 |
| Injection, fentanyl citrate, 0.1 mg | 129 | $1 | $2 |
| Injection, midazolam hydrochloride, per 1 mg | 121 | $0 | $0 |
| Remote patient monitoring device, 30 days | 114 | $36 | $181 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 112 | $1,016 | $3,942 |
| Office visit, established patient (20-29 min) | 83 | $62 | $209 |
| Hospital follow-up visit, high complexity | 78 | $86 | $304 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 73 | $14 | $57 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 72 | $18 | $79 |
| New patient office visit, complex (60-74 min) | 66 | $155 | $595 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 57 | $25 | $71 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 53 | $37 | $147 |
| Initial hospital admission, high complexity | 53 | $126 | $593 |
| Programming of dual lead pacemaker system | 50 | $51 | $168 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 38 | $19 | $79 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 38 | $621 | $2,031 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 37 | $1,723 | $9,180 |
| Nuclear medicine study of heart muscle blood flow by pet | 36 | $133 | $691 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 36 | $87 | $700 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 35 | $314 | $1,351 |
| Cardiac catheterization | 33 | $732 | $3,018 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 30 | $18 | $75 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 24 | $8 | $31 |
| New patient office visit (45-59 min) | 19 | $112 | $477 |
| Injection of chemical agent into single incompetent vein of leg using ultrasound guidance | 18 | $980 | $4,029 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 17 | $66 | $265 |
| Evaluation of cardiac rhythm monitor system | 16 | $31 | $104 |
| Ultrasound study of arm and leg arteries | 16 | $41 | $248 |
| Destruction of first incompetent vein of arm or leg using radiofrequency and imaging guidance | 15 | $788 | $4,716 |
| Office visit, established patient (10-19 min) | 15 | $42 | $120 |
| Coronary stent placement | 13 | $396 | $1,789 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
4.7% high complexity
52.2% medium
43.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$22,854
Total received (2018-2024)
Avg $3,265/year across 7 years
Top 17% in TX for cardiovascular disease
30
Companies
534
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,311 (53.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$5,793 (25.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$4,750 (20.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$577
2023$1,010
2022$1,028
2021$2,187
2020$2,177
2019$12,827
2018$3,048
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
BARD PERIPHERAL VASCULAR, INC.
$5,793
Bard Peripheral Vascular, Inc.
$5,557
Abbott Laboratories
$4,129
Janssen Pharmaceuticals, Inc
$1,059
Boston Scientific Corporation
$876
AstraZeneca Pharmaceuticals LP
$782
Medtronic, Inc.
$734
E.R. Squibb & Sons, L.L.C.
$698
Amgen Inc.
$633
Novartis Pharmaceuticals Corporation
$558
PFIZER INC.
$383
Terumo Medical Corporation
$327
Medtronic Vascular, Inc.
$299
Boehringer Ingelheim Pharmaceuticals, Inc.
$266
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$192
Philips Electronics North America Corporation
$162
Merck Sharp & Dohme LLC
$58
Ra Medical Systems, Inc.
$41
ABIOMED
$34
Gilead Sciences, Inc.
$34
CORDIS US CORP.
$34
Amarin Pharma Inc.
$33
BOSTON SCIENTIFIC CORPORATION
$32
Tactile Systems Technology Inc
$27
Impulse Dynamics (USA) Inc.
$24
W. L. Gore & Associates, Inc.
$23
Actelion Pharmaceuticals US, Inc.
$22
HeartFlow, Inc.
$20
Chiesi USA, Inc.
$13
Kowa Pharmaceuticals America, Inc.
$12
Top 3 companies account for 67.7% of total payments
Associated products mentioned in payments ›
(5139) IGT Fixed SV TnM · (9266) ELCA · AVVIGO Guidance System · Allure CRT Pacemaker · Allure Quadra RF CRT Pacemaker · Assurity Pacemaker · BRILINTA · CAMZYOS · CHANTIX · CRT Leads · CRT-Ds · CardioMEMS HF System · Confirm Rx · Corlanor · DABRA · Durata Defibrillation ICD Lead · ELIQUIS · EMBLEM MRI S-ICD · ENDURANT IIS · ENTRESTO · Ellipse ICD · FARXIGA · FFRct · Flexitouch Plus · Fortify Assura · GORE VIABAHN VBX Balloon Expandable Endo · General - Vascular Intervention · GlideWire · Glidesheath · Guidezilla · HARMONY · HawkOne · HeartMate 3 Left Ventricular Dev · IGT D Peripheral · IN.PACT Admiral · INGEVITY MRI · INGEVITY+ · Image Guided Therapy Devices _ Coronary · Impella · JARDIANCE · KENGREAL · LATITUDE Communicator Power Supply · LEQVIO · LIFESTENT · LIFESTREAM · LINQ II · LUTONIX · LUX-Dx Insertable Cardiac Monitor · LifeVest · Livalo · MAMBA · MRI Ready Leads · Merlin Connectivity and Remote · Navicross · ONYX FRONTIER · OPTIMIZER · OptiSense Pacing Lead · Optisure Defibrillation ICD Lead · Quadra Allure MP RF CRT Pacemkr · Quadra Assura CRT Defibrillator · Quartet CRT Lead · RAIDEN3T · RAIN SHEATH · RESOLUTE ONYX · ROTABLATOR · ROTAPRO · Repatha · Resolute · Reveal LINQ · RotaWire and wireClip Torquer · Rotablator Rotational Atherectomy System Console Kit · SYNERGY · Stellarex · THORATEC HEARTMATE 3 LVAS IMPLANT KIT · TR Band · UPTRAVI · Unify Assura CRT Defibrillator · VENASEAL · VENOVO · VERQUVO · VYNDAQEL · Vascepa · Venovo · WATCHMAN · XARELTO · Xience Sierra Coronary Stent · Xience Sierra Coronary Stent System · myLUX Patient Kit with mobile device
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (54%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $305 per 100 Medicare services performed
Geographic Context
Cardiovascular Diseases within 10 mi
34
Per 100K population
3.9
County median income
$58,859
Nearest hospital
RIO VISTA BEHAVIORAL HEALTH
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. De Luca is a clinical cardiology specialist, with above-average Medicare volume (top 7% in TX), and high industry engagement (low-engagement, top 17%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. De Luca experienced with contrast dye for imaging (iodine-based)?
Based on Medicare claims data, Dr. De Luca performed 2,539 contrast dye for imaging (iodine-based) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. De Luca receive payments from pharmaceutical companies?
Yes. Dr. De Luca received a total of $22,854 from 30 companies across 534 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. De Luca's costs compare to other cardiovascular diseases in El Paso?
Dr. De Luca's average Medicare payment per service is $91. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. De Luca) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Cardiovascular Diseases in El Paso
Browse cardiovascular diseases in El Paso ranked by procedure volume and transparency data.
Highest volume
Top Cardiovascular Diseases in TX
Cardiovascular Diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiovascular Diseases in TX
Which TX cardiovascular diseases receive the most from drug and device companies.
By company
BARD PERIPHERAL VASCULAR, INC. Payments to Doctors
See all physicians who received payments from BARD PERIPHERAL VASCULAR, INC..
By company
Bard Peripheral Vascular, Inc. Payments to Doctors
See all physicians who received payments from Bard Peripheral Vascular, Inc..
By company
Abbott Laboratories Payments to Doctors
See all physicians who received payments from Abbott Laboratories.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology